Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP5834 + Panitumumab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP5834 | ASP-5834|ASP 5834 | KRAS Inhibitor 30 | Limited information is currently available on ASP5834, a putative pan-KRAS degrader (Aug 2025). | |
| Panitumumab | Vectibix | ABX-EGF | EGFR Antibody 72 | Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07094204 | Phase I | ASP5834 ASP5834 + Panitumumab | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | Recruiting | USA | 0 |